Paysign (PAYS) vs SOPHiA GENETICS SA (SOPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Paysign (PAYS) has outperformed SOPHiA GENETICS SA (SOPH) over the past year, gaining 90.8% versus a gain of 37.2%. Over five years, PAYS leads with a +399.5% price change compared with -56.9% for SOPH. Paysign is the larger company by market cap ($556.9 million vs $533.7 million), about 1.0 times the size.
Paysign converts more of its revenue into profit, with a net margin of 9.2% versus -102.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PAYS | SOPH |
|---|---|---|
| Share price | $9.80 | $6.23 |
| Market cap | $556.89M | $533.65M |
| 1-day change | -2.63% | -6.74% |
| YTD return | +90.10% | +33.40% |
| 1-year return | +90.84% | +37.22% |
| 5-year return | +399.49% | -56.89% |
| P/E ratio (TTM) | 29.68 | — |
| Forward P/E | 15.93 | — |
| EPS (TTM) | $0.33 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | $77.27M |
| Revenue growth (YoY) | +40.50% | +18.56% |
| Net income (latest FY) | $7.55M | $-79.00M |
| Gross margin | 59.39% | 67.40% |
| Operating margin | 8.98% | -91.76% |
| Net margin | 9.21% | -102.24% |
| 52-week high | $16.15 | $8.98 |
| 52-week low | $3.08 | $4.01 |
| Distance from 52-week high | -39.35% | -30.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +51.20% | +56.50% |
| Average volume | 1.04M | 678.76K |
| Shares outstanding | 56.85M | 85.66M |
| Employees | 226 | 415 |
| Sector | Technology | Technology |
| Industry | EDP Services | EDP Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PAYS has outperformed SOPH by 53.6 percentage points over the past year.
- Paysign is more profitable, keeping 9.2 cents of every revenue dollar as net income versus -102.2 cents for SOPHiA GENETICS SA.
- Paysign grew revenue faster in its latest fiscal year (+40.50% vs +18.56%).
About Paysign
PAYS stock →Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States.
Technology · EDP Services · 226 employees
About SOPHiA GENETICS SA
SOPH stock →SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Technology · EDP Services · 415 employees
PAYS vs SOPH FAQ
Which is bigger, Paysign or SOPHiA GENETICS SA?
Paysign (PAYS) is larger, with a market capitalization of $556.89M compared with $533.65M for SOPHiA GENETICS SA (SOPH).
Which stock has performed better over the past year, PAYS or SOPH?
PAYS returned +90.84% over the past 12 months, compared with +37.22% for SOPH (price return, excluding dividends). Past performance does not predict future results.
Are Paysign and SOPHiA GENETICS SA in the same industry?
Yes. Both are classified in the EDP Services industry within the Technology sector.